Peng Leong

CBO and Head of Brain Aging at BioAge

Speaker

Dr. Peng Leong leads efforts at BioAge to execute strategic transactions that convert prioritized drug targets into a portfolio of therapies for treating diseases of aging, and activities specific to brain aging. Peng has played a key role in building BioAge’s pipeline, including in-licensing Azelaprag that is being studied in an on-going Phase 2 trial for obesity, and establishing research collaborations with leading pharma companies. In prior roles at Merck KGaA, Chiron, Kazia Therapeutics, DRI Healthcare and investment banking, Peng acquired or sold billions of dollars in pharmaceutical product rights. Dr. Leong received his BSc and PhD in Biochemistry from the University of Toronto, Canada and an MBA from the University of California, Berkeley.